CoChat

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

Open access
Fonseca, Vivian A., Alvarado-Ruiz, Ricardo, Raccah, Denis, Boka, Gabor, Miossec, Patrick, Gerich, John E., on behalf of the EFC6018 GetGoal-Mono Study Investigators · 2012 · Diabetes Care

The DOI matches its Crossref record, with a small difference in title or year; 18 of the 21 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To assess efficacy and safety of lixisenatide monotherapy in type 2 diabetes. RESEARCH DESIGN AND METHODS: Randomized, double-blind, 12-week study of 361 patients not on glucose-lowering therapy (HbA1c 7–10%) allocated to one of four once-daily subcutaneous dose increase regimens: lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, and then 20 μg; n = 120), lixisenatide 1-step (10 μg for 2 weeks and then 20 μg; n = 119), placebo 2-step (n = 61), or placebo 1-step (n = 61) (placebo groups were combined for analyses). Primary end point was HbA1c change from baseline to week 12. RESULTS: Once-daily lixisenatide significantly improved HbA1c (mean baseline 8.0%) in both groups (least squares mean change vs. placebo: −0.54% for 2-step, −0.66% for 1-step; P < 0.0001). Significantly more lixisenatide patients achieved HbA1c <7.0% (52.2% 2-step, 46.5% 1-step) and ≤6.5% (31.9% 2-step, 25.4% 1-step) versus placebo (26.8% and 12.5%, respectively; P < 0.01). Lixisenatide led to marked significant improvements of 2-h postprandial glucose levels and blood glucose excursions measured during a standardized breakfast test. A significant decrease in fasting plasma glucose was observed in both lixisenatide groups versus placebo. Mean decreases in body weight (∼2 kg) were observed in all groups. The most common adverse events were gastrointestinal—nausea was the most frequent (lixisenatide 23% overall, placebo 4.1%). Symptomatic hypoglycemia occurred in 1.7% of lixisenatide and 1.6% of placebo patients, with no severe episodes. Safety/tolerability was similar for the two dose regimens. CONCLUSIONS: Once-daily lixisenatide monotherapy significantly improved glycemic control with a pronounced postprandial effect (75% reduction in glucose excursion) and was safe and well tolerated in type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1935

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. A: Mean change (±SEM) in HbA1c over time. B: Percentage of patients achieving HbA1c goals <7.0% and ≤6.5%. LOCF, Last Observation Carry Forward.
Figure 1 Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. A: Mean change (±SEM) in HbA1c over time. B: Percentage of patients achieving HbA1c goals <7.0% and ≤6.5%. LOCF, Last Observation Carry Forward.CC BY-NC-ND · PubMed Central
Figure 2 Changes in postbreakfast glucose parameters from baseline after 12-weeks' treatment with lixisenatide (according to dose increase regimen) or placebo. LS mean change in mean (±SEM) 2-h PPG levels is shown. LS mean change in 2-h glucose excursion is also shown. Data are from patients undergoing a standardized breakfast meal test at selected sites. Glucose excursion = 2-h PPG, plasma glucose 30 min before the meal test before study drug administration. Mean ± SD baseline values for 2-h PPG: 13.99 ± 4.78 mmol/L (placebo), 14.67 ± 3.78 mmol/L (lixisenatide 2-step), 14.55 ± 3.36 mmol/L (lixisenatide 1-step). Mean ± SD baseline values for glucose excursion: 4.72 ± 3.65 mmol/L (placebo), 5.45 ± 3.02 mmol/L (lixisenatide 2-step), 5.25 ± 2.89 mmol/L (lixisenatide 1-step). To convert mmol/L to mg/dL, divide by 0.0555.
Figure 2 Changes in postbreakfast glucose parameters from baseline after 12-weeks' treatment with lixisenatide (according to dose increase regimen) or placebo. LS mean change in mean (±SEM) 2-h PPG levels is shown. LS mean change in 2-h glucose excursion is also shown. Data are from patients undergoing a standardized breakfast meal test at selected sites. Glucose excursion = 2-h PPG, plasma glucose 30 min before the meal test before study drug administration. Mean ± SD baseline values for 2-h PPG: 13.99 ± 4.78 mmol/L (placebo), 14.67 ± 3.78 mmol/L (lixisenatide 2-step), 14.55 ± 3.36 mmol/L (lixisenatide 1-step). Mean ± SD baseline values for glucose excursion: 4.72 ± 3.65 mmol/L (placebo), 5.45 ± 3.02 mmol/L (lixisenatide 2-step), 5.25 ± 2.89 mmol/L (lixisenatide 1-step). To convert mmol/L to mg/dL, divide by 0.0555.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 3

  1. Distiller, 2008, Pharmacokinetics and pharmacodynamics of a new GLP-1 agonist AVE0010 in type 2 diabetes patients (Abstract), Diabetes, 57, A154
  2. Ratner, 2009, Post-meal pharmacodynamic profile of AVE0010, a once-daily GLP-1 receptor agonist, in patients with type 2 diabetes inadequately controlled on metformin (Abstract), Diabetologia, 52, S60
  3. Liu, 2009, Pharmacokinetics and safety of the GLP-1 agonist AVE0010 in patients with renal impairment (Abstract), Diabetes, 59, A149

Cited by

See all 220

Metadata

Authors
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators
Affiliations
  • Tulane University (US)
  • Cardioprevent, Durango, Mexico
  • Hôpital Sainte-Marguerite (FR)
  • Sanofi (France) (FR)
  • University of Rochester Medicine (US)
Corresponding author
Fonseca, Vivian A.
Venue
Diabetes Care
Published
2012-05-11
Volume
35
Issue
6
Pages
1225-1231
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2108122035
Cited by
218
References
21
Citations by year
2025: 5 · 2024: 6 · 2023: 8 · 2022: 7 · 2021: 7 · 2020: 9 · 2019: 11 · 2018: 19 · 2017: 27 · 2016: 23 · 2015: 20 · 2014: 31 · 2013: 39 · 2012: 5
FWCI
24.38
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
lixisenatide, GLP-1 receptor agonists, type 2 diabetes, monotherapy, glycemic control, HbA1c, postprandial blood glucose, fasting blood glucose, weight loss, nausea, hypoglycemia, dose escalation, drug safety and tolerability, subcutaneous administration, dyslipidemia
MeSH terms
Glucagon-Like Peptide-2 Receptor, Adult, Aged, Aged, 80 and over, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Nausea, Peptides, United States, Blood Glucose Self-Monitoring, Body Mass Index, Treatment Outcome, Postprandial Period, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. https://app.cochat.ai/papers/10.2337/dc11-1935
The paper
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators. (2012). Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy. Diabetes Care. https://doi.org/10.2337/dc11-1935

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.